Company news

enGene Therapeutics Inc. news in 2025

enGene Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

enGene Reports Full Year 2025 Financial Results and Provides Business Update

December 22, 2025

Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors

December 16, 2025

enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

December 2, 2025

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

November 13, 2025

enGene Announces Proposed Public Offering of Common Shares

November 12, 2025

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

November 11, 2025

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

November 10, 2025

enGene to Participate in Upcoming Investor Conferences

November 6, 2025

enGene Named a BioSpace 2026 Best Places to Work Winner

November 4, 2025

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 1, 2025

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

September 30, 2025

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

September 11, 2025

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

September 3, 2025

EnGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 4, 2025

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

July 8, 2025

FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

June 25, 2025

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

June 12, 2025

enGene Announces the Resignation of its Chief Medical Officer

June 4, 2025

enGene to Present at the Jefferies Global Healthcare Conference

May 29, 2025

enGene Names Amy Pott as Chief Global Commercialization Officer

May 28, 2025

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

April 1, 2025

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

March 10, 2025

enGene to Participate in the Leerink Partners Global Healthcare Conference

March 4, 2025

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 3, 2025

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

January 29, 2025

Decks in 2025